Where we are going
The MyClimb Study will inform the development and clinical trial design of potential new treatments, including gene therapies.
About gene therapy
While cardiomyopathy has been diagnosed and understood as a condition for more than 100 years, over the past 20-30 years there has been a greater understanding of the genetic causes of the disease.
Genes are segments of DNA that provide instructions to create the proteins our body needs to function. Certain genetic mutations disrupt these instructions and impact proteins that control the ability of the heart to pump blood through the body.
Gene therapy is a growing field that seeks to address genetic mutations. Greater understanding of the genetic causes of heart disease could lead to better treatments in the future including gene therapies.
The MyClimb Study is a critical first step in the journey to unlocking the questions around cardiomyopathy that have challenged families, paving the way for the development of new treatments, including gene therapies.
